Stock INM INMED PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials InMed Pharmaceuticals Inc.

Equities

INM

CA4576376012

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:01 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.23 USD -8.73% Intraday chart for InMed Pharmaceuticals Inc. -20.72% -44.71%
Apr. 18 InMed Pharmaceuticals Inc. Appoints David G. Morgan to its Scientific Advisory Board CI
Apr. 04 InMed Pharmaceuticals Inc. Announces Additional Preclinical Data Demonstrating INM-901'S Positive Pharmacological Effects in the Potential Treatment of Alzheimer's Disease CI

Valuation

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 58.35 43.78 31.73 12.41 4.083 1.907 -
Enterprise Value (EV) 1 40.31 43.78 22.34 12.41 4.083 1.907 1.907
P/E ratio -4.23 x -3.69 x -2.04 x - - - -
Yield - - - - - - -
Capitalization / Revenue - - - 8.4 x 0.73 x 0.26 x 0.21 x
EV / Revenue - - - 8.4 x 0.73 x 0.26 x 0.21 x
EV / EBITDA -4,315,845 x - -2,550,526 x - - - -
EV / FCF - - - - - - -
FCF Yield - - - - - - -
Price to Book - - - - - - -
Nbr of stocks (in thousands) 209 209 322 820 3,328 6,057 -
Reference price 2 279.4 209.6 98.53 15.14 1.227 0.3149 0.3149
Announcement Date 9/19/19 9/8/20 9/24/21 9/23/22 9/29/23 - -
1CAD in Million2CAD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025
Net sales 1 - - - 1.478 5.594 7.298 9.123
EBITDA -13.52 - -12.44 - - - -
EBIT 1 -13.64 -12.11 -12.59 -18.71 -11.33 -13.74 -15.55
Operating Margin - - - -1,265.96% -202.6% -188.2% -170.49%
Earnings before Tax (EBT) -13.26 -11.86 -12.93 - - - -
Net income -13.26 -11.86 -12.93 - - - -
Net margin - - - - - - -
EPS -66.00 -56.75 -48.24 - - - -
Free Cash Flow - - - - - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 9/19/19 9/8/20 9/24/21 9/23/22 9/29/23 - -
1CAD in Million
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - 0.3377 0.4031 0.6983 - 3.126 1.243 1.682 2.005 2.407
EBITDA - - - - - - - - - -
EBIT 1 -3.711 -5.635 -4.846 -4.134 - -0.6984 -3.618 -2.312 -2.876 -5.026
Operating Margin - -1,668.73% -1,202.22% -592% - -22.34% -291% -137.46% -143.41% -208.85%
Earnings before Tax (EBT) - - - - - - - - - -
Net income - - - - -2.697 - - - - -
Net margin - - - - - - - - - -
EPS - - - - -0.8099 - - - - -
Dividend per Share - - - - - - - - - -
Announcement Date 11/10/21 2/14/22 5/13/22 9/23/22 5/15/23 9/29/23 11/14/23 2/13/24 - -
1CAD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025
Net Debt - - - - - - -
Net Cash position 18 - 9.39 - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow - - - - - - -
ROE (net income / shareholders' equity) - - - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex 0.04 - 0 - - - -
Capex / Sales - - - - - - -
Announcement Date 9/19/19 9/8/20 9/24/21 9/23/22 9/29/23 - -
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Quarterly revenue - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
INMED PHARMACEUTICALS INC. Stock InMed Pharmaceuticals Inc.
-44.71% 1.39M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. INM Stock
  4. Financials InMed Pharmaceuticals Inc.